Literature DB >> 3885129

Immunology of corneal allograft rejection. Associated human leucocyte populations.

E Young, W J Stark.   

Abstract

Human serum samples and peripheral blood mononuclear leucocytes (PBML) were collected from ten corneal transplant recipients over a two-year period at intervals before and after surgery, and during and after episodes of immunologic (rejection) reaction. Serum was monitored for the development of antibodies to histocompatibility antigens and PBML were stained with a panel of monoclonal reagents specific for T cell and for monocyte populations using indirect immunofluorescence. Patients who demonstrated an elevation in the Leu 2a+ (suppressor/cytotoxic) T cell population following an immunologic reaction ultimately accepted their grafts, whereas patients whose Leu 2a+ population was unaffected developed irreversible graft clouding. Additionally, a direct positive correlation between the development of elevated levels of lymphocytotoxic antibodies and helper T cells was noted in some patients during immunologic reactions. Neither DR-positive nor monocyte population changes demonstrated any consistent correlation with rejection episodes or final graft outcome.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3885129     DOI: 10.1016/s0161-6420(85)34053-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  3 in total

1.  Corneal allograft rejection in bilateral penetrating keratoplasty: clinical and laboratory studies.

Authors:  R F Meyer
Journal:  Trans Am Ophthalmol Soc       Date:  1986

2.  Systemic (serum) soluble interleukin-2 receptor levels in corneal transplant recipients.

Authors:  C S Foster; H K Wu; A Merchant
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

3.  Intercellular adhesion molecule-1 in human corneal endothelium. Modulation and function.

Authors:  V M Elner; S G Elner; M A Pavilack; R F Todd; B Y Yue; A R Huber
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.